[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
January 2016

Exclusion of Patients With Kidney Disease From Cardiovascular Trials

Author Affiliations
  • 1Division of Nephrology, Department of Medicine, University of California–San Francisco
  • 2Division of Nephrology, Department of Medicine, San Francisco VA Medical Center, San Francisco, California
JAMA Intern Med. 2016;176(1):124-125. doi:10.1001/jamainternmed.2015.6403

Despite a high prevalence of kidney disease (KD)—ranging from 30% to 60%—among patients with cardiovascular disease (CVD)1 and the association of KD with worse cardiovascular outcomes,2 two previous systematic reviews observed underrepresentation of patients with KD in randomized clinical trials of cardiovascular interventions published from 1985 through 2005.1,2 Eighty-six of 153 (56.2%) to 69 of 86 trials (80.2%) excluded patients with KD, and only 6 of 86 (7.0%) to 15 of 153 (9.8%) studies reported patients’ kidney function at the start of the trial.

First Page Preview View Large
First page PDF preview
First page PDF preview
×